NAGE Niagen Bioscience Inc.

  1. Stocks
  2. Healthcare
  3. NASDAQ: NAGE

Price (delayed)

$3.5

Market cap

$278.76M

P/E Ratio

14.58

Dividend/share

N/A

EPS

$0.24

Enterprise value

$214.78M

Sign up for free to view scoring metrics ?
Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 91

ChromaDex Corporation operates as a bioscience company focusing on healthy aging. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches on nicotinamide ...

Highlights
The stock's price to earnings (P/E) is 60% less than its last 4 quarters average of 36.1
The equity rose by 49% year-on-year and by 8% since the previous quarter
NAGE's quick ratio is up by 16% year-on-year but it is down by 7% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.chromadex.com
Peers: NAII EXEL

Key stats

What are the main financial stats of NAGE

NAGE stock price

How has the Niagen Bioscience stock price performed over time
Intraday
1.74%
1 week
-8.85%
1 month
-29.01%
1 year
-70.12%
YTD
-44.97%
QTD
-20.63%

Financial performance

How have Niagen Bioscience's revenue and profit performed over time
Revenue
$130.42M
Gross profit
$83.83M
Operating income
$13.08M
Net income
$18.64M
Gross margin
64.3%
Net margin
14.3%
The company's net income rose by 32% YoY and by 7% QoQ
The gross profit has increased by 24% year-on-year
NAGE's operating margin is down by 21% since the previous quarter and by 19% year-on-year
The revenue has grown by 21% YoY

Price vs fundamentals

How does NAGE's price correlate with its fundamentals

Growth

What is Niagen Bioscience's growth rate over time

Valuation

What is Niagen Bioscience stock price valuation
NAGE P/E details
P/E
14.58
P/B
3.4
P/S
2.14
EV/EBIT
10.9
EV/EBITDA
10.11
EV/Sales
1.65
The stock's price to earnings (P/E) is 60% less than its last 4 quarters average of 36.1
The company's EPS rose by 33% YoY and by 9% QoQ
NAGE's price to book (P/B) is 66% lower than its last 4 quarters average of 9.8 and 56% lower than its 5-year quarterly average of 7.7
The equity rose by 49% year-on-year and by 8% since the previous quarter
NAGE's price to sales (P/S) is 62% lower than its last 4 quarters average of 5.6 and 43% lower than its 5-year quarterly average of 3.7
The revenue has grown by 21% YoY

Efficiency

How efficient is Niagen Bioscience business performance
NAGE's return on invested capital is down by 27% year-on-year and by 14% since the previous quarter
The company's return on equity fell by 25% YoY and by 2.7% QoQ
Niagen Bioscience's return on assets has decreased by 16% YoY
The company's return on sales rose by 12% YoY and by 7% QoQ

Dividends

What is NAGE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for NAGE.

Financial health

How did Niagen Bioscience financials performed over time
The total assets has grown by 41% YoY and by 7% from the previous quarter
The current ratio has increased by 26% year-on-year but it has declined by 5% since the previous quarter
Niagen Bioscience's debt is 97% less than its equity
NAGE's debt to equity has dropped by 50% year-on-year and by 25% since the previous quarter
The equity rose by 49% year-on-year and by 8% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.